source
- Windward prices $175M IPO to advance China-licensed lung drugsThe Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.BioPharma Dive · 38m ago↗ source
- FDA faces over 1,000 vacant positions as staffing shortage strains pharma oversightThe FDA currently has more than a thousand open jobs, reflecting a deep staffing shortfall that began after a large wave of departures last year. The agency lost 1,343 employees at its CBER and CD…
- FDA’s fast-track voucher program appears to be discontinued, report finds